Team:Uppsala/human-practice

From 2013.igem.org

(Difference between revisions)
 
(8 intermediate revisions not shown)
Line 77: Line 77:
                                                 <li><a href="https://2013.igem.org/Team:Uppsala/metabolic-engineering">Metabolic engineering</a>
                                                 <li><a href="https://2013.igem.org/Team:Uppsala/metabolic-engineering">Metabolic engineering</a>
                                                     <ul>
                                                     <ul>
-
                                                                 <li><a href="https://2013.igem.org/Team:Uppsala/p-coumaric-acid">P-coumaric acid</a></li>
+
                                                                 <li><a href="https://2013.igem.org/Team:Uppsala/p-coumaric-acid">p-Coumaric acid</a></li>
                                                                 <li><a href="https://2013.igem.org/Team:Uppsala/resveratrol">Resveratrol</a></li>
                                                                 <li><a href="https://2013.igem.org/Team:Uppsala/resveratrol">Resveratrol</a></li>
<li><a href="https://2013.igem.org/Team:Uppsala/lycopene">Lycopene</a></li>
<li><a href="https://2013.igem.org/Team:Uppsala/lycopene">Lycopene</a></li>
Line 98: Line 98:
<li><a href="https://2013.igem.org/Team:Uppsala/modeling" id="list_type1"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/6/63/Uppsala2013_Modeling.png"></a>
<li><a href="https://2013.igem.org/Team:Uppsala/modeling" id="list_type1"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/6/63/Uppsala2013_Modeling.png"></a>
<ul>
<ul>
-
<li><a href="https://2013.igem.org/Team:Uppsala/P-Coumaric-acid-pathway">P-Coumaric acid</a></li>
+
<li><a href="https://2013.igem.org/Team:Uppsala/P-Coumaric-acid-pathway">Kinetic model</a></li>
<li><a href="https://2013.igem.org/Team:Uppsala/modeling-tutorial">Modeling tutorial </a></li>
<li><a href="https://2013.igem.org/Team:Uppsala/modeling-tutorial">Modeling tutorial </a></li>
 +
 +
<li><a href="https://2013.igem.org/Team:Uppsala/toxicity-model">Toxicity model</a></li>
</ul></li>
</ul></li>
<li><a href="https://2013.igem.org/Team:Uppsala/parts" id="list_type2"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/e/eb/Uppsala2013_parts.png"></a></li>
<li><a href="https://2013.igem.org/Team:Uppsala/parts" id="list_type2"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/e/eb/Uppsala2013_parts.png"></a></li>
Line 118: Line 120:
<li><a href="https://2013.igem.org/Team:Uppsala/public-opinion">Public opinion </a></li>
<li><a href="https://2013.igem.org/Team:Uppsala/public-opinion">Public opinion </a></li>
                                                 <li><a href="https://2013.igem.org/Team:Uppsala/Outreach">High school & media </a></li>
                                                 <li><a href="https://2013.igem.org/Team:Uppsala/Outreach">High school & media </a></li>
-
 
+
<li><a href="https://2013.igem.org/Team:Uppsala/bioart">BioArt</a></li>
 +
<li><a href="https://2013.igem.org/Team:Uppsala/LactonutritiousWorld">A LactoWorld</a></li>
 +
<li><a href="https://2013.igem.org/Team:Uppsala/killswitches">Killswitches</a></li>
 +
<li><a href="https://2013.igem.org/Team:Uppsala/realization">Patent</a></li>
</ul></li>
</ul></li>
<li><a href="https://2013.igem.org/Team:Uppsala/attribution" id="list_type4"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/5/5d/Uppsala2013_Attributions.png"></a></li>  
<li><a href="https://2013.igem.org/Team:Uppsala/attribution" id="list_type4"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/5/5d/Uppsala2013_Attributions.png"></a></li>  
Line 136: Line 141:
  <div class="HP_awesome_texting">
  <div class="HP_awesome_texting">
  <h1 class="main-title">Human practice</h1>
  <h1 class="main-title">Human practice</h1>
-
This year, when we decided on our iGEM project, one of our main focuses was that it should be well integrated with our human practice projects. Because our project involves GM food, which is a topic that raises many ethical and safety issues, we wanted to find out what the public knew and to create a broad debate on the subject. We wanted to do a project that was not only engaging for us students, but also something that could engage people in general.<br><br>
 
-
We think we have had great succes on this matter. Our first step was to create something concrete that could illustrate our vision. To achieve this we created a concept product in the form of a yoghurt that would contain our modified bacteria.  With this, we could more easily start debates and inform people about synthetic biology. <br><br>
 
-
We have been suprised by the interest people have shown for our project. We have been seen on television, people have followed us on facebook and we arranged a very well attended SynBioDay with over 200 participants.<br><br>
+
 
 +
This year, when we decided on our iGEM project, one of our main focuses was that it should be well integrated with our human practice projects. We think that human practice is one of the most important parts of iGEM.
 +
<br><br>
 +
Our goal is to create GM food. To be able to realize our vision we have to consider alot of different aspects.
 +
<br><br>
 +
Is it safe to eat GM food?<br>
 +
Will people want to eat genetically engineered bacteria? <br>
 +
How can we easily communicate our project idea? <br>
 +
If we commercialize our idea, should we patent it? <br>
 +
Can we patent biobricks and do we even want that? <br>
 +
How should we see on safety issues, can our organism spread in the ecosystem? Should we add a killswitch? <br>
 +
Why is GMO restricted in Europe and what does politicians think of this? <br>
 +
<br>
 +
<b>Conclussion</b><br>
 +
We have tried to answer all of these questions in our human practice project. The conclussion we have made is that we think the future of GM food is bright and that it is absolutely realizable.
 +
 
 +
 
 +
 
 +
 
 +
 
  </div>
  </div>
Line 178: Line 200:
<div id="main_cow" >
<div id="main_cow" >
<img src="https://static.igem.org/mediawiki/2013/e/e8/Uppsala2013_pic1.png" name="imageTag" />
<img src="https://static.igem.org/mediawiki/2013/e/e8/Uppsala2013_pic1.png" name="imageTag" />
 +
 +
<div style="position: relative; top: -440px; left: 230px; width:100px; height: 100px; z-index: 1000;">
 +
<a href="https://2013.igem.org/Team:Uppsala/realization" style="display:block;height:100%;width:100%;"></a>
 +
</div>
 +
<div style="position: relative; top: -300px; left: -80px; width:250px; height: 200px;">
 +
<a href="https://2013.igem.org/Team:Uppsala/killswitches""><img src="https://static.igem.org/mediawiki/2013/4/4b/Uppsala_question1.png" style="width: 250px; "></a>'
 +
</div>
 +
<div style="position: relative; top: -450px; left: 250px; width:200px; height: 200px; ">
 +
<a href="https://2013.igem.org/Team:Uppsala/LactonutritiousWorld" > <img src="https://static.igem.org/mediawiki/2013/1/17/Uppsala_question2.png" style="width: 200px;"></a>
 +
</div>
 +
 +
<script type="text/javascript">
<script type="text/javascript">

Latest revision as of 19:57, 27 October 2013

Human practice

This year, when we decided on our iGEM project, one of our main focuses was that it should be well integrated with our human practice projects. We think that human practice is one of the most important parts of iGEM.

Our goal is to create GM food. To be able to realize our vision we have to consider alot of different aspects.

Is it safe to eat GM food?
Will people want to eat genetically engineered bacteria?
How can we easily communicate our project idea?
If we commercialize our idea, should we patent it?
Can we patent biobricks and do we even want that?
How should we see on safety issues, can our organism spread in the ecosystem? Should we add a killswitch?
Why is GMO restricted in Europe and what does politicians think of this?

Conclussion
We have tried to answer all of these questions in our human practice project. The conclussion we have made is that we think the future of GM food is bright and that it is absolutely realizable.
'